Inactivated vaccine against viral pneumogastroenteritis in cattle and calves and method for prophylaxis of viral pneumogastroenteritis

FIELD: veterinary science, virology.

SUBSTANCE: invention proposes inactivated vaccine against pneumogastroenteritis in cattle and calves. Vaccine comprises a mixture of inactivated viruses of infectious rhinotracheitis, viral diarrhea, rota-, corona-, respiratory-syncytial infection and parainfluenza-3 of cattle and adjuvant. Suspensions of viruses in the mixture are taken in the ratio = 1:1:1:1:0.5:0.5, respectively, by volume. The titer value for viruses of infectious rhinotracheitis, viral diarrhea, rotaviral and coronoviral infection = 107.0 - 108.5 TCD50/ml and for viruses of parainfluenza-3 and respiratory-syncytial infection = 106.5 - 107.5 TCD50/ml. Also, invention proposes a method for prophylaxis of total pneumogastroenteritis in cattle and calves involving administrations of such vaccine. The proposed vaccine is more effective and shows enhanced immunogenicity that provides enhancing the prophylactic effect in its using. Invention can be used in animal husbandry.

EFFECT: improved, enhanced and valuable properties of vaccine.

2 cl, 4 tbl

 

The invention relates to the field of biotechnology and veterinary medicine and the receipt and use of vaccines for the prevention of pneumohydrodevices bovine (cattle) and especially newborn calves.

Massive gastrointestinal and respiratory diseases of cattle and calves are widely distributed worldwide and cause enormous economic damage to countries with highly developed animal husbandry.

Polietiologic nature of these diseases, widespread cause of their pathogens, laboratory diagnosis difficult and the lack of a universal and highly effective means of specific prophylaxis doing battle with them is futile.

The most common cause of gastro-intestinal diseases of cattle and calves are Rota - and coronaviruses cattle, and diseases with respiratory syndrome is most often caused by infectious bovine rhinotracheitis virus, parainfluenza type 3, and respiratory syncytial virus. Virus diarrhea of cattle can cause pathology as gastrointestinal and respiratory tracts.

In the occurrence of diseases of calves in different situations leading role played by some other of the above pathogens that circulate in the herd often in the form of various associations. Loss of calves from these diseases can reach 15-30%, and sabol is of young and adult animals leads to reduced productivity. In addition, the disease is often complicated by bacterial infections.

For the specific prevention of certain viral diseases proposed a number of live and inactivated vaccines, mainly mono - and bivalent. The use of such vaccines in a number of cases in adult animals leads to positive results only when the viral component included in the vaccine, and the etiological agent causing the disease, consistent with each other.

Known vaccine "TREPAK (VIEW)" for the prevention of infectious bovine rhinotracheitis, parainfluenza-3 virus diarrhea - diseases of the mucous membranes of cattle. The vaccine contains antigens from attenuated strains of the virus of infectious bovine rhinotracheitis, parainfluenza-3 and diarrhoea diseases of the mucous. As the strains of the viruses it contains a strain of Herpes virus bovis "TC-a(VIEW)-2 activity 104,5-106,5TCD50/mlthe strain of Virus diarrhea - mucosal disease bovinum "BK-1(B-1)N 28" with an activity of 104,0-106,0TCD50/mlthe strain Paramyxovirus "PTC-45/86" with an activity of 105,0-107,0TCD50/ml(patent RU 2111011 AND 61 TO 39/295 published 20.05.1998).

The disadvantage of this vaccine is low, the protection of cattle from pneumohydrodevices, as well as the lack of specificity and immunogenicity.

Known associated vaccine against Rota-, corona-, herpes and esche is aioneu diarrhea of newborn calves. The vaccine contains as viral antigens inactivated culture suspensions of strains of Bovine rotavirus "III-1", Bovine coronavirus, CM-1 and Bovine Herpesvirus "TKA-VIEW-IN-2", and as the antigen of Escherichia inactivated cell suspension of E. coli strains containing adhesin C and A20 (patent RU 2145236, a 61 K 39/295 published 10.02.2000).

The disadvantage of this vaccine is incomplete protection of cattle from pneumohydrodevices, as well as the lack of specificity and immunogenicity.

In some cases, part of the famous vaccines, especially designed for the protection of calves, includes antigens of pathogens causing secondary infection.

A common disadvantage of all known vaccines for use against mass infectious respiratory and gastro-intestinal diseases of cattle and calves is their poor performance in the first narrow antigenic spectrum and possibly insufficiently high specific activity included in the composition of the components. In addition, the use of many of them has some limitations. This primarily refers to the use of live vaccines against infectious rhinotracheitis and bovine viral diarrhea for pregnant cows and newborn calves.

The closest analogue is inactivated combined vaccine against infectious bovine rhinotracheitis, paragraph the a-3, viral diarrhea, respiratory syncytial, Rota-, coronaviruses disease of calves "combopack"containing production inactivated strains 6 viruses: infectious bovine rhinotracheitis, parainfluenza-3, viral diarrhea, respiratory syncytial, Rota - and coronaviruses diseases of cattle (Guidance on the use of inactivated vaccine combined against infectious bovine rhinotracheitis, parainfluenza-3, viral diarrhea, respiratory syncytial, Rota-, coronaviruses disease of calves, combopack, No. 13-3-04/0703 from 20.03.2003 approved by the veterinary Department 20.03.2003).

The disadvantage of this vaccine is its lack of potency and immunogenicity.

The technical result of the invention is to increase the specific activity, efficacy, and immunogenicity.

The invention relates to an inactivated vaccine against viral pneumohydrodevices cattle and calves, containing a mixture of inactivated virus of infectious bovine rhinotracheitis, virus diarrhea, Rota-, corona-, respiratory syncytial infection and parainfluenza-3 cattle and adjuvant, wherein the inactivated suspensions of infectious bovine rhinotracheitis virus, viral diarrhea, rotavirus and coronavirus infection it contains a titer of 107,5-10 8,5TCD50/mlfor each virus, parainfluenza virus-3 and respiratory syncytial infection in title 106,5107,5TCD50/mlwhile inactivated suspensions of viruses in the mixture taken in a ratio by volume 1:1:1:1:0,5:0,5 accordingly, in the following ratio of components of the vaccine, vol.%:

A mixture of inactivated suspensions of viruses70-90
Adjuvant10-30

as well as a way to prevent mass pneumohydrodevices cattle and calves, including subcutaneous administration of such inactivated vaccine.

The offered vaccine is a pink or colorless liquid with loose sediment grayish-white color, easily broken in a uniform suspension by shaking. Vaccine at 2-6°preserves the original activity of not less than 12 months. The vaccine is injected subcutaneously twice with an interval of 21 to 30 days to adult males at a dose of 2 ml calves at the dose of 1 ml Dry cows begin to vaccinate 2-3 weeks before insemination. Pregnant cows Vaccinium for 2-2 .5 months before calving, calves 3-4 weeks after birth. This way the vaccine was most effective. It combines active and passive (maternal) immunity.

The invention illustri is : the following examples.

Example 1. For the preparation of vaccines use the 6 strains of viruses, which are typical representatives of the 5 families of viruses pathogenic for cattle under natural conditions. These viruses are propagated separately in cell culture, where they accumulate in the title 7,0-8,5 lg TCD50/ml. Production of the seed of each virus unite among themselves, to inactivate the complete loss of viral infectivity mixture, add adjuvant, poured into vials are closed with rubber stoppers and rolled aluminum caps.

Study of different modes of inactivation of viruses showed different resistance to the action of formalin at 37°With (table 1). Quite reliable and at the same time gentle conditions inactivation selected: virus IRT - 0.3% formalin for 72 hours, for the rest of viruses 0.2% formalin for 48 hours.

Table 1

Modes of inactivation of the virus with formalin at 37°
VirusesThe concentration of formalin
0,1%0,2%0,3%
The duration of inactivation (hours)
244872244872 244872
RTI-------++
VD-----++++
PG-3-----++++
Roth---++++++
Crown--+++++++
PC--+--++++
- the virus is not inactivated
+ inactivated virus

Example 2. Under optimal culture conditions (origin and age of the cell culture, the method of growing cells and virus multiplicity of infection, duration of incubation, the processing is pilirovanny culture, storage of viral material) accumulation of virus reaches significant levels: virus RTI, Rota - and coronaviruses ≥8,0 lg TCD50/mlviruses PG-3, VD and P-C≥7,0 lg TCD50/ml. Established that the strains do not play a significant role either in the accumulation, or antigenicity of the viruses (table 2).

Example 3. When optimizing the conditions of manufacture of the vaccines studied the value of content and the ratio of viral antigens and the amount of adjuvant. Assessment conducted by seroconversion in vaccinated seronegative calves. Best results are obtained if the virus antigens RTI, VD, Rota-, corona-, PG-3 and R-With installed activity was taken in the following proportions: 1:1:1:1:0,5 and 0.5 (table 3). The content of the adjuvant in a mixture of viral antigens (volume/ volume) should be 20% (table 4).

At 2-6°With the vaccine remains active for 12 months.

Table 2

Accumulation and antigenic properties of different strains 6 virus propagated in cell cultures
VirusStrainsAccumulation of virus (lg TCD50/mlin cell culture MDCThe duration of curing (days)The titer of neutralizing antibodies (VNA) in Guinea pigs immunized with inactivated antigens
RTIB-257,0-8,52-332-128
TC-7,0-8,52-332-64
VDBD-N7,0-8,5232-256
BD-R7,0-8,5216-256
PG-3B-196,5-7,52-416-32
PTC-45/866,5-7,52-416-32
RothK-887,0-8,5232-512
RP-827,0-8,5232-256
CrownKV-907,0-8,53-432-512
K-227,0-8,53-432-512
PCPC-896,5-7,52-316-64
PC-716,5-7,52-316-64

Copyright viral strains deposited in the prescribed manner to the Museum of strains of the Institute of Virology. DI Ivanovo RAMS.

Table 3

Antigenicity of viral components at different is the ratio of the vaccine
VirusesThe content and antigenicity of viral components
Virus (%)The VNA titerVirus (%)The VNA titerVirus (%)The VNA titer
RTI1532-642032-1282564-128
VD1564-1282064-25625128-256
PG-31516-1282032-1281016-64
Roth1532-2562064-2561016-128
Crown2064-2561032-1281532-64
PC2064-2561032-641532-128

GOA 20%
Table 4

Soda neigh hydrate of aluminum oxide (GOA) and the antigenicity of the vaccine
VirusesAntigen content (%)Antigenicity VNA for Guinea pigs
GOA 10%
RTI2032-6432-128
VD2032-25664-256
PG-32032-6432-128
Roth2032-12864-256
Crown1016-12832-256
PC1032-12864-128

Example 4. Epizootic vaccine efficacy was tested in 1998-2003, in farms of Russia and Belarus, where the observed pathology of the respiratory and digestive system. The morbidity and mortality of calves in the first 1-2 months after birth reached 10-30%. Laboratory tests confirmed the presence of these farms all diseases (in various combinations), the pathogens which enter into the composition of the vaccine. On the etiological nature of the diseases these farms differed among themselves as well as individual farm, the same farm. After the vaccine, the incidence of disease and death of animals was reduced by 2-3 times.

Thus, it was found that farms for breeding and fattening bovine viral agents (RTI, VD, PG-3, Rota-, crown -, and P-C viruses are the primary cause of mass disease with lesions of the respiratory and digestive the sory organs. These diseases violating the reproductive function and reduce the productivity of adult cattle, especially hard to occur in young animals, causing the death of 15-30% of the calves soon after birth. The protection of such farms from significant economic losses is an important task. This goal can be achieved by the application of the proposed inactivated vaccine.

1. Inactivated vaccine against viral pneumohydrodevices cattle and calves, containing a mixture of inactivated virus of infectious bovine rhinotracheitis, virus diarrhea, Rota-, corona-, respiratory syncytial infection and parainfluenza-3 cattle and adjuvant, wherein the inactivated suspensions of infectious bovine rhinotracheitis virus, viral diarrhea, rotavirus and coronavirus infection it contains a titer of 107,0-108,5TCD50/mlfor each virus, parainfluenza virus-3 and respiratory syncytial infection in title 106,5-107,5TCD50/mlwhile inactivated suspensions of viruses in the mixture taken in a ratio by volume 1:1:1:1:0,5:0,5 accordingly, in the following ratio of components of the vaccine, vol.%:

A mixture of inactivated suspensions of viruses70-90
Adjuvant 10-30

2. The way to prevent mass pneumohydrodevices cattle and calves, including subcutaneous administration of the vaccine, characterized in that the use of inactivated vaccine according to claim 1.



 

Same patents:

The invention relates to biotechnology and associated with new vaccines

The invention relates to biotechnology and concerns associated vaccine containing a single drug multiple antigens
The invention relates to medicine, namely to Pediatrics, and can be used for vaccination against pertussis, diphtheria and tetanus

The invention relates to the field of medicine and relates to multivalent vaccine compositions containing acellular pertussis components of the vaccine, diphtheria toxoid, the tetanus toxoid and inactivated poliovirus

The invention relates to the field of veterinary biotechnology, Virology and Microbiology

The invention relates to the specific prophylaxis of plague, infectious hepatitis and parvovirus enteritis in dogs

FIELD: veterinary science, virology.

SUBSTANCE: invention proposes inactivated vaccine against pneumogastroenteritis in cattle and calves. Vaccine comprises a mixture of inactivated viruses of infectious rhinotracheitis, viral diarrhea, rota-, corona-, respiratory-syncytial infection and parainfluenza-3 of cattle and adjuvant. Suspensions of viruses in the mixture are taken in the ratio = 1:1:1:1:0.5:0.5, respectively, by volume. The titer value for viruses of infectious rhinotracheitis, viral diarrhea, rotaviral and coronoviral infection = 107.0 - 108.5 TCD50/ml and for viruses of parainfluenza-3 and respiratory-syncytial infection = 106.5 - 107.5 TCD50/ml. Also, invention proposes a method for prophylaxis of total pneumogastroenteritis in cattle and calves involving administrations of such vaccine. The proposed vaccine is more effective and shows enhanced immunogenicity that provides enhancing the prophylactic effect in its using. Invention can be used in animal husbandry.

EFFECT: improved, enhanced and valuable properties of vaccine.

2 cl, 4 tbl

FIELD: veterinary microbiology, virology, biotechnology.

SUBSTANCE: invention proposes vaccine that comprises as antigens the following components, vol. %: inactivated suspension of cells of hemolytic strains of microorganism M. bovis with the total concentration 100-120 billion cells in 1 cm3: strain M. bovis "G97-VNIVI", 4.0-5.0; strain M. bovis "SHZ-01", 4.0-5.0; inactivated cultural suspension of the strain Herpesvirus bovis type I "TKA-VIEV-V2" with infectious titer 107.0 - 107.5 TCD50/ml, 78.0-83.0; 6% solution of aluminum hydroxide gel, the balance. Vaccine enhances accumulation of specific protective antibodies in serum blood of vaccinated animals and provides the development of immunity against infectious keratoconjunctivitis that is retained for one year.

EFFECT: enhanced effectiveness and valuable properties of vaccine.

4 tbl, 6 ex

FIELD: veterinary virology and biotechnology.

SUBSTANCE: claimed vaccine contains antigenic material from PRRS virus strain, reproduced in passaged cell culture Marc-145 and inactivated with aminoethylethyleneimine (AEEI), antigenic material from PPVI virus strain reproduced in passaged YPK cell culture and inactivated with AEEI, and oil adjuvant in effective ratio. Vaccine represents white or white-rose emulsion. Vaccine is intramuscularly (behind ear) administered to animal in dose of 2 cm3 independently of age thereof. Immunity in vaccinated animals appears over 21-30 days after vaccination and remains for 6 months or more. Vaccine of present invention induces high levels of antibodies against PRRS and PPVI and provides durable passive immunity in young stocks up to 20-25-days age.

EFFECT: innoxious vaccine useful in animal protection of neonatal age from field viral PRRS and PPVI agents.

14 cl, 8 tbl, 11 ex

FIELD: medicine, infectious diseases, vaccines.

SUBSTANCE: invention relates to development and using mixed vaccines used in prophylaxis and treatment of infections being at first hepatitis B. The mixed vaccine comprises hepatitis B virus surface antigen adsorbed on aluminum phosphate and mixed with antigens of another pathogens adsorbed on aluminum hydroxide or aluminum phosphate taken in the amount n = 3-4 and chosen from diphtheria, tetanus, whooping cough and Haemophilus influenza b. At least one antigen among antigens n and other pathogens is adsorbed on aluminum hydroxide. Aluminum phosphate confers the resistance to hepatitis B surface antigen in polyvalent compositions of vaccines. Polyvalent vaccines are stable and show higher immunological indices in their administration in children.

EFFECT: improved preparing method, valuable medicinal properties of vaccines.

5 cl, 16 tbl, 11 ex

FIELD: veterinary science.

SUBSTANCE: the present innovation deals with immunization of down-calving cows with a live dry culture associated vaccine against paragrippe-3 (PG) and infectious rhinotracheitis in cattle at the dosage of 2 ml 1.5 mo before calving at simultaneous intramuscular injection of Selecor at the dosage of 10 mcg/kg animal's body weight; in 14 d one should introduce Selecor once more at the same dosage; then Selecor should be once injected intramuscularly for calves born in above-mentioned cows for 0.5-1 h after their birth. The innovation increases colostral cell and humoral immunity in calves, decrease sickness rate and accelerates the recovery.

EFFECT: higher efficiency of prophylaxis.

3 ex, 6 tbl

FIELD: biotechnology, veterinary virology.

SUBSTANCE: the present innovation deals with elaborating epizootically and ecologically safe associated inactivated vaccine that creates tense immunity simultaneously against IRT and PG-3 in cattle. The method deals with cultivating vaccine strains of IRT and PG-3 viruses in a cell culture, sampling virus-containing culture liquid, inactivation of virus and addition of an adjuvant. Moreover, as vaccine strains it is necessary to apply the strain of TC-A/C of IRT virus grown in passage cell culture MDVC, at activity of 7.5-8.0 lg TCD50/cu. cm, and the strain PG/C-2002 of PG-3 virus grown in passage cell culture PC at activity of 7.5-8.0 lg TCD50/cu. cm. On sampling virus-containing culture liquid one should carry out inactivation of virus of every strain with theotropin for about 5-7 d at 36.5-37.5° C, pH being 7.2-7.5. Moreover, one should add theotropin to virus-containing liquid of every strain at final concentration of 0.1%, and then mix inactivated virus-containing liquids of both strains at the ratio of 1:1 and add adjuvant at the quantity of 20% that consists of 6%-aluminum hydroxide and saponin gel. The innovation enables to obtain epizootically and ecologically safe vaccine that creates tense immunity in vaccinated animals, being stable at storage.

EFFECT: higher efficiency.

2 ex, 1 tbl

FIELD: veterinary science.

SUBSTANCE: one should carry out immunization in down-calving cows with dry culture associated alive vaccine against paragrippe-3 and infectious rhinotracheitis in cattle at the dosage of 2 ml 1.5 mo before calving and simultaneously it is necessary to inject ligavirin subcutaneously at the dosage of 5 ml. In 14 d one should introduce ligavirin once more at the same dosage. Calves born in these cows should be once injected with ligavirin intramuscularly during 0.5-1 h after calving at the dosage of 1 ml. The innovation enables to increase efficiency of immunoprophylaxis of viral respiratory diseases in calves.

EFFECT: higher efficiency of immunoprophylaxis.

3 ex, 6 tbl

FIELD: veterinary virology.

SUBSTANCE: the suggested vaccine contains a virus-containing material obtained at combined cultivation of avian smallpox virus upon cell culture of hen's fibroblasts "VGNKI-3" strain and virus of Newcastle disease "M-VNII VV&M" strain. Virus content in cell culture corresponds to 0.02-0.04 and 0.02-0.08 TCD/cell, correspondingly. The suggested virus vaccine is of high immunogenicity.

EFFECT: higher efficiency of vaccine application.

1 ex

FIELD: gene engineering, virology, veterinary.

SUBSTANCE: cattle vaccine contains plasmid including F gene, G gene or F and G genes of bovine respiratory syncitial virus. Vaccine of present invention in useful in cattle breeding for bovine immunization against respiratory syncitial virus.

EFFECT: new vaccine against bovine respiratory pathologies.

7 cl, 11 dwg, 16 ex

FIELD: medicine; bioengineering.

SUBSTANCE: combined vaccine contains inactivated Teotropine culture virus-containing raw epizootic isolate of pig's enzootic encephalomyelitis (Teschen disease) virus of initial biological activity 107.5-109.0 lg "ТЦД"50/cm3 and inactivated Teotropine culture virus-containing raw vaccine strain of Aujeszky's disease virus of initial biological activity 107.0-108.0 lg "ТЦД"50/cm3, and oily adjuvant in the following ratio, wt %: inactivated Teotropine culture virus-containing raw epizootic isolate of pig's enzootic encephalomyelitis (Teschen disease) virus - 23-27, inactivated Teotropine culture virus-containing raw vaccine strain of Aujeszky's disease virus - 23-27, Teotropine - 0.03-0.05, oily adjuvant - the rest.

EFFECT: high immunogenicity, areactogenicity, harmlessness and storage stability.

2 tbl, 2 ex

Up!